{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:04:27Z","timestamp":1792461867450,"version":"4.5.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We report a case of slipped capital femoral epiphysis (SCFE), an on target skeletal toxicity of a pan-FGFR TKI inhibitor, erdafitinib. A 13-year-old boy was diagnosed to have an optic pathway\/hypothalamic glioma with signs of increased intracranial pressure and obstructive hydrocephalus requiring placement of ventriculo-peritoneal (VP) shunt. Sequencing of the tumor showed FGFR1-tyrosine kinase domain internal tandem duplication (FGFR1-KD-ITD). He developed hypothalamic obesity with rapid weight gain and BMI &amp;gt;30. At 12 weeks of treatment with erdafitinib, he developed persistent knee pain. X-ray of the right hip showed SCFE. Erdafitinib was discontinued, and he underwent surgical pinning of the right hip. MRI at discontinuation of erdafitinib showed a 30% decrease in the size of the tumor, which has remained stable at 6 months follow-up. Our experience and literature review suggest that pediatric patients who are treated with pan-FGFR TKIs should be regularly monitored for skeletal side effects.<\/jats:p>","DOI":"10.3389\/fonc.2024.1399356","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T04:44:28Z","timestamp":1716525868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child"],"prefix":"10.3389","volume":"14","author":[{"given":"Meziane","family":"Brizini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Drimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Streilein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Drapeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wrogemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Anne","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Del Bigio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magimairajan Issai","family":"Vanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02705-7","article-title":"Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers","volume":"42","author":"Brown","year":"2023","journal-title":"Oncogene"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00390","article-title":"Rare FGFR Oncogenic Alterations in sequenced Pediatric solid and brain tumors suggest FGFR is a relevant molecular target in childhood cancer","volume":"6","author":"De La Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2611","article-title":"Tang B et\u00a0al: Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30410","article-title":"Slipped capital femoral epiphyses: A major on-target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients","volume":"70","author":"Farouk Sait","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.21.02838","article-title":"Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the national cancer institute-children\u2019s oncology group pediatric MATCH trial","volume":"40","author":"Parsons","year":"2022","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/PO.20.00444","article-title":"Debio 1347, an oral FGFR inhibitor: results from a single-center study in pediatric patients with current or refractory FGFR-altered Gliomas","volume":"5","author":"Farouk Sait","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81069-7","article-title":"Fibroblast Growth Factor Receptor 3 is a negative regulator of bone growth","volume":"84","author":"Deng","year":"1996","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1242\/dev.128.19.3867","article-title":"Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains","volume":"128","author":"Wang","year":"2001","journal-title":"Development"},{"key":"B10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/jcm13071889","article-title":"Exploring the impact of novel anti-cancer therapies on jaw osteonecrosis and other bones: A comprehensive review","volume":"13","author":"Konarski","year":"2024","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00003086-199601000-00003","article-title":"The demographics of slipped capital femoral epiphysis","volume":"322","author":"Loder","year":"1996","journal-title":"Clin Orthop Relat Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-008-1123-3","article-title":"Impact of obesity in the diagnosis of SCFE and knee problems in obese children","volume":"39","author":"Restrepo","year":"2009","journal-title":"Pediatr Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/01.bpo.0000184651.34475.8e","article-title":"Relationship between Body Mass Index and slipped capital femoral epiphysis","volume":"25","author":"Manoff","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"B16","article-title":"Hyperphosphatemia","volume-title":"StatPearls","author":"Goyal","year":"2023"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000001339","article-title":"Clinical and radiographic characteristics of atypical slipped capital femoral epiphysis","volume":"39","author":"Chung","year":"2019","journal-title":"J Pediatr Orthop"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1399356\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T04:44:31Z","timestamp":1716525871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1399356\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":17,"alternative-id":["10.3389\/fonc.2024.1399356"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1399356","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"article-number":"1399356"}}